A method of producing virus-interferon inducer

 

(57) Abstract:

The invention relates to the field of the biotechnology industry, in particular the production of virus-inducer for the production of human leukocyte interferon. The method involves obtaining virus-interferon inducer; the resulting stock material (strain "H" of the virus of Newcastle disease GKV 2348) diluted in phosphate-saline buffer with the addition of 10.0% D(+)-lactose, introducing allantoin cavity of chick embryos at a concentration of 106JRS/50/0.2 ml, followed by incubation and selection vaccinated liquid. The method ensures titers of interferon activity 16000 - 18000 IU/ml against 11000 - 14000 IU/ml in analogue. table 1.

The invention relates to the field of medical industry, in particular the production of virus-inducer for the production of human leukocyte interferon.

In the production of human leukocyte interferon to be used as a virus-interferon inducer vaccine strain "H" of the virus of Newcastle disease (VBN). This strain is used in many countries around the world, producing human leukocyte interferon for medical and veterinarian what vaistai when receiving leukocyte interferon humans or animals.

A method of obtaining virus-interferon inducer by cultivation of a strain of "H" of the virus of Newcastle disease in 9-11 day old chick embryos [1] . Infecting dose of virus is 106JRS/50/0,2 ml of the Virus-inductor diluted in 0.1 M phosphate-buffered saline. This dose is entered in allantoin cavity of the embryo syringe under conditions of sterility. The embryos are then incubated for 48 h at (320,5)oC. After incubation, the embryos are cooled at 4oC and sucked off vaccinated allantoin liquid, which after the necessary controls are used as virus-interferon inducer. Vaccinated fluid must meet the following requirements: to be bacteriologically sterile, have hemagglutinin activity (HA) 256 units, infectious titer not less than 1011JRS/50/ml When using this inductor in the production of human leukocyte interferon receive interferon with antiviral activity 11 000 - 14 000 IU/ml

The objective of the invention is increased interferon-inducing ability of viral inducer.

To solve the problem in the method of producing virus-interferon inducer uterine material (strain "H" virus diseases Nuturing embryos at a concentration of 106JRS/50/0.2 ml, followed by incubation and selection vaccinated liquid.

A distinctive feature of the proposed method is the addition of D(+)-lactose in phosphate-saline buffer at a dilution of uterine strain, allowing for more high titers of interferon activity 16 000 - 18 000 IU/ml versus 11 000 - 14 000 IU/ml in the prototype (see. table).

Example 1. Strain "H" of the virus of Newcastle disease (GKV N 2348) was used as a uterine strain. To obtain the production strain in allantoin cavity 9-10 day chick embryo injected with conditions of sterility at a concentration of 106JRS/50/0.2 ml of the original suspension uterine strain diluted in phosphate-buffered saline, with the addition of 10.0% D(+)-lactose. Incubated for 48 h at a temperature of (320,5)oC. After incubation, the embryos are cooled in air for 18-20 h atoC, sucked off vaccinated allantoin liquid. The titer of interferon-type, obtained with this inductor is 16 000 IU/ml

Example 2. Strain "H" of the virus of Newcastle disease (GKV N 2348) was used as a uterine strain. To obtain the production strain in allantoin cavity 9-10 day chick embryo Amma, diluted in phosphate-buffered saline, with the addition of 10.0% D(+)-lactose. Incubated for 48 h at a temperature of (320,5)oC. After incubation, the embryos are cooled in air for 18-20 h atoC, sucked off vaccinated allantoin liquid. The titer of interferon-type, obtained with this inductor is 18 000 IU/ml

Sources of information

1.RF patent N 2140284, class a 61 K 38/21, publ. 27.10.99.

A method of producing virus-inducer of interferon, including the introduction of the virus of Newcastle disease, strain "N", GKV 2348 in phosphate-buffered saline in allantoin cavity of chick embryos and their subsequent incubation and selection vaccinated liquid, characterized in that the use of phosphate-saline buffer with addition of 10% D (+)-lactose.

 

Same patents:

The invention relates to biotechnology and Microbiology and is a method of obtaining biomass of recombinant strains of E. coli containing plasmid DNA encoding the biosynthesis of cytokines with the properties of factors, tumor necrosisand(TNF-alpha and TNF-beta), granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) human and bearing as a selective marker gene bla (resistance to ampicillin)

The invention relates to biotechnology

The invention relates to the field of veterinary medicine

The invention relates to the field of veterinary Virology, namely, the vaccine against Newcastle disease of birds, intended for oral administration

The invention relates to the field of veterinary Virology, namely the production of biological preparations for immunization of poultry against Newcastle disease

The invention relates to the field of veterinary Virology, namely, the vaccine against Newcastle disease of birds, intended for oral administration

The invention relates to veterinary Virology and biotechnology, and in particular to methods of obtaining living culture vaccines against distemper, and can be used at the enterprises of biological industry

The invention relates to a method for producing high-performance dry VirusWall from strain La Sota against Newcastle disease for prophylactic immunization of hens and chickens in a safe and threatened by Newcastle disease industrial farms and individual farms) poultry

The invention relates to veterinary medicine and relates to a drug for treatment and prophylaxis of plague, proviruses enteritis and hepatitis dogs (immunogen")
The invention relates to medicine, the pharmaceutical industry and relates to the creation of new dosage forms containing CLI
The invention relates to medicine, namely to physiotherapy
The invention relates to medicine, in particular to urology, and can be used for the treatment of benign prostatic hyperplasia
Remedy // 2172180
The invention relates to medicine, in particular to the pharmaceutical industry

The invention relates to medicine and can be used for the treatment of acute viral respiratory infections (ARI) in children
The invention relates to urology and is intended for the integrated treatment endourethral warts

The invention relates to medicine, in particular to combustology, and can be used for prevention of early sepsis in children tyazheloobozhzhennykh
Up!